Alzamend Neuro Inc Ordinary Shares ALZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.55
- Day Range
- $1.51–1.52
- 52-Week Range
- $0.84–2.55
- Bid/Ask
- $1.44 / $1.52
- Shares Outstanding
- 4.83M
- Market Cap
- $7.53M
- Volume/Avg
- 4,877 / 81,780
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.alzamend.com
Valuation
Metric | ALZN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.29 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ALZN |
|---|---|
Quick Ratio | 0.53 |
Current Ratio | 1.31 |
Interest Coverage | −1,324.50 |
Quick Ratio
ALZN
Profitability
Metric | ALZN |
|---|---|
Return on Assets (Normalized) | −160.17% |
Return on Equity (Normalized) | −226.57% |
Return on Invested Capital (Normalized) | −226.44% |
Return on Assets
ALZN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|hl?Q<<< | LOCK|Q!@m# | $138B | |||
| Moderna Inc MRNA | LOCK|@#N^?G | LOCK|T@x | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!<p^Yn | LOCK|m$%W | $93B | |||
| argenx SE ADR ARGX | LOCK|K!LX>Yv | LOCK|#& | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%rbf!T | LOCK|P%c | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&#>x#>D | LOCK|!FJv | $30B | |||
| Incyte Corp INCY | LOCK|!F^c#lL | LOCK|>kR | $24B | |||
| BioNTech SE ADR BNTX | LOCK|j#K$x> | LOCK|s$ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|D#f#c? | LOCK|@dP!Y | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|><kvFM> | LOCK|@L | $15B |
United States